View on GitHub

This database release contains relevant FDA Oncology updates from March 2025.

Database content updates

Revised entries:

  • (FDA) Pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the treatment of patients with HER2-positive gastric adenocarcinoma received traditional FDA approval after previously receiving accerated approval.

Three entries were updated to replace the unicode \u2265 with >=.